1. [Humanization of Murine Monoclonal anti-hTNF Antibody: The F10 Story].
- Author
-
Efimov GA, Raats JMH, Chirivi RGS, van Rosmalen JWG, and Nedospasov SA
- Subjects
- Adalimumab isolation & purification, Adalimumab pharmacology, Animals, Anti-Inflammatory Agents, Non-Steroidal, Antibodies, Monoclonal history, Antibodies, Monoclonal isolation & purification, Antibodies, Monoclonal pharmacology, Antibodies, Monoclonal, Humanized history, Antibodies, Monoclonal, Humanized isolation & purification, Antibodies, Monoclonal, Humanized pharmacology, Arthritis, Rheumatoid genetics, Arthritis, Rheumatoid immunology, Arthritis, Rheumatoid pathology, Cloning, Molecular, Gene Expression, History, 20th Century, History, 21st Century, Humans, Infliximab isolation & purification, Infliximab pharmacology, Mice, Psoriasis drug therapy, Psoriasis genetics, Psoriasis immunology, Psoriasis pathology, Spondylitis, Ankylosing drug therapy, Spondylitis, Ankylosing genetics, Spondylitis, Ankylosing immunology, Spondylitis, Ankylosing pathology, Tumor Necrosis Factor-alpha genetics, Tumor Necrosis Factor-alpha immunology, Adalimumab biosynthesis, Antibodies, Monoclonal biosynthesis, Antibodies, Monoclonal, Humanized biosynthesis, Arthritis, Rheumatoid drug therapy, Infliximab biosynthesis, Tumor Necrosis Factor-alpha antagonists & inhibitors
- Abstract
Tumor necrosis factor (TNF) is a proinflammatory cytokine implicated in pathogenesis of multiple autoimmune and inflammatory diseases. Anti-TNF therapy has revolutionized the therapeutic paradigms of autoimmune diseases and became one of the most successful examples of the clinical use of monoclonal antibodies. Currently, anti-TNF therapy is used by millions of patients worldwide. At the moment, fully human anti-TNF antibody Adalimumab is the best-selling anti-cytokine drug in the world. Here, we present a story about a highly potent anti-TNF monoclonal antibody initially characterized more than 20 years ago and further developed into chimeric and humanized versions. We present comparative analysis of this antibody with Infliximab and Adalimumab.
- Published
- 2017
- Full Text
- View/download PDF